Medtronic to Webcast Renal Denervation Investor and Analyst Briefing on November 7

DUBLIN, October 14, 2022 /PRNewswire/ — Medtronic plc (NYSE:MDT), a global health technology leader, today announced that the company will host a webcast to provide an update on its Medtronic Coronary and Renal Denervation business during the annual scientific sessions from the American Heart Association (AHA 2022) on Monday, November 7, 2022at 5:00 p.m. CST. The webcast will feature remarks from the leadership of Medtronic Coronary and Renal Denervation, including comments on the 6-month results of the SPYRAL HTN-ON MED (ON MED) randomized trial. These data will be presented in a late-breaking scientific session at AHA 2022 on November 7the presentation of ON MED data to start around 3:38 p.m. CST. The company intends to issue a press release on the results of ON MED on November 7 at the beginning of the ON MED last minute scientific session presentation.

The live audio webcast of the Investor and Analyst Briefing can be accessed by clicking on the Investor Events link at on November 7, 2022. Within 24 hours of the webcast, a replay will be available on the same webpage. The Investor and Analyst Briefing is not part of the official AHA 2022 program.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the global health technology leader boldly tackling the toughest health challenges facing humanity by researching and finding solutions. Our mission – to relieve pain, restore health and extend life – unites a global team of more than 95,000 passionate people in 150 countries. Our technologies and therapies address 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. With our diverse knowledge, insatiable curiosity and desire to help everyone in need, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we deliver insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we design the extraordinary. For more information about Medtronic (NYSE:MDT), visit and follow @Medtronic on Twitter and LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports filed with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.


Erika Winkels

Ryan Weispfenning

Public relations

Investor Relations



SOURCEMedtronic plc